We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Theravance Biopharma Inc | NASDAQ:TBPH | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09 | -0.95% | 9.38 | 9.09 | 11.59 | 9.60 | 9.25 | 9.45 | 339,462 | 01:00:00 |
From May 2022 to May 2024
By Josh Beckerman
Theravance Biopharma said Tuesday that the Food and Drug Administration granted Orphan Drug Designation status to ampreloxetine for treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy.
The company said it is "diligently progressing" its registrational Phase 3 study of ampreloxetine, a once-daily norepinephrine reuptake inhibitor.
Theravance shares rose 5 cents during the regular session to $11.38 and were flat after hours.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 09, 2023 18:43 ET (22:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Theravance Biopharma Chart |
1 Month Theravance Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
